4FDA. Full preseribing information for Fanapt[ EB/OL]. [ 2009 - 05-06]. http: //www. accessdata. fda. gov/drugsatfda docs/ label/2009/022192 lbl. pdf.
5KALKMAN HO, SUBRAMANIAN N, HOYER D. Extended radioligand binding profile of iloperidone : a broad spectrum dopamine/ serotonin/norepinephrine receptor antagonist for the management of psychotic disorders [ J ]. Neuropsychopharmacology, 2001,25 ( 6 ) :904 -914.
6SZEWCZAK MR, CORBETT R, RUSH DK, et al. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent [ J]. J Pharmacol Exp Ther, 1995,274( 3 ) : 1404 - 1413.
7SUBRAMANIAN N, KALKMAN HO. Receptor profile ofP88- 8991 and P95412113, metabolites of the novel antipsychotic iloperidone [ J ]. Prog Neuropsychopharmacol Biol Psychiatry, 2002, 26(3): 553-560.
8SAINATI SM, HUBBARD JW, CHI E, et al. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic [ J]. J Clin Pharmacol, 1995,35(7) :713 -720.
9POTKIN SG, LITMAN RE, TORRES R, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies [ J ]. J Clin Psychopharmacol, 2008,28 ( 2 Suppl 1 ) : S4 - S11.
10CUTLER AJ, KALALI AH, WEIDEN PJ, et al. Four week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia[ J]. J Clin Psychopharmacol,2008,28 ( 2 Suppl 1 ) : S20 -S28.
